Stryker Corporation (NYSE:SYK) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Stryker Corporation has been given an average analyst recommendation of "Moderate Buy", with fourteen out of twenty brokerages rating it a buy and six a hold.
• The company's stock has a 12-month average price target of approximately $430.33, and its latest quarterly earnings beat consensus estimates with revenues of $6.02 billion.
• Stryker will pay a quarterly dividend of $0.84 per share on October 31st, reflecting an annualized dividend yield of 0.9% and a payout ratio of 44.5%.

Stryker Corporation (NYSE:SYK - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twenty brokerages that are covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $430.3333.

Several brokerages have recently issued reports on SYK. BTIG Research reiterated a "buy" rating on shares of Stryker in a research report on Monday, July 14th. Wall Street Zen downgraded Stryker from a "buy" rating to a "hold" rating in a research note on Friday. Rothschild & Co Redburn assumed coverage on Stryker in a research note on Thursday, September 18th. They issued a "neutral" rating and a $420.00 price target for the company. Evercore ISI upped their price objective on shares of Stryker from $390.00 to $415.00 and gave the stock an "outperform" rating in a report on Tuesday, July 8th. Finally, Truist Financial set a $415.00 target price on shares of Stryker and gave the company a "hold" rating in a research note on Monday, August 4th.

Stryker Stock Performance

Shares of SYK opened at $369.02 on Tuesday. The firm has a fifty day moving average of $385.33 and a 200-day moving average of $379.18. The company has a market cap of $141.08 billion, a price-to-earnings ratio of 48.88, a price-to-earnings-growth ratio of 2.66 and a beta of 0.93. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. Stryker has a 1 year low of $329.16 and a 1 year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $5.92 billion. During the same period last year, the firm posted $2.81 EPS. Stryker's quarterly revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, equities analysts anticipate that Stryker will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker's dividend payout ratio (DPR) is currently 44.50%.

Insider Buying and Selling

In other news, insider Viju Menon sold 500 shares of the business's stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the sale, the insider owned 12,511 shares of the company's stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the transaction, the director directly owned 3,222,108 shares of the company's stock, valued at $1,212,962,556.60. This represents a 5.84% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.20% of the company's stock.

Hedge Funds Weigh In On Stryker

Several large investors have recently made changes to their positions in SYK. Mid American Wealth Advisory Group Inc. bought a new stake in shares of Stryker in the 2nd quarter worth approximately $26,000. Elevation Point Wealth Partners LLC acquired a new position in Stryker in the second quarter worth approximately $28,000. Sachetta LLC increased its holdings in shares of Stryker by 58.7% in the second quarter. Sachetta LLC now owns 73 shares of the medical technology company's stock valued at $29,000 after buying an additional 27 shares in the last quarter. Kilter Group LLC acquired a new stake in shares of Stryker during the 2nd quarter valued at $29,000. Finally, Howard Hughes Medical Institute bought a new stake in shares of Stryker during the 2nd quarter worth $29,000. Institutional investors own 77.09% of the company's stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.